Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2019

View Archived Issues

New chemogenetics system could find clinical use

Kinase target as stroke target

Precision Biosciences initiates phase I/IIa study of PBCAR-0191 in relapsed/refractory B-ALL and NHL

CQDM awards grant to IMV and its collaborators to develop DPX-SurMAGE

Arch Biopartners receives approval for phase I study of Metablok in Australia

Transcription factor may be colitis immunotherapy target

Millendo Therapeutics initiates pivotal phase IIb/III ZEPHYR study of livoletide

Phase II data presented for MS-1819-SD recombinant lipase

IMP-761 inhibits antigen-specific T-cell-mediated immune responses in vitro and in vivo

Positive topline results presented from pivotal phase III EMPOWUR study of vibegron

OBE-022 demonstrates promising safety and PK in the first part of the PROLONG study

Trial supports uninterrupted edoxaban for atrial fibrillation undergoing catheter ablation

FDA places partial clinical hold on venetoclax trials in multiple myeloma

ICT completes pre-IND meeting with FDA for CAR-T candidate ICTCAR-014

Newave Pharmaceutical discloses new Bcl-2 inhibitors

Phase II trial begins in Taiwan with TJ-202 for relapsed or refractory multiple myeloma

Plex Pharmaceuticals presents dual FKBP12/FKBP52 inhibitors

New Tec family kinase inhibitors synthesized at GB005

FDA approves Zulresso for postpartum depression

BioTheryX patents IL-1beta, IL-6, IL-2 and TNF-alpha production inhibitors

The University of Kansas identifies new endoplasmin inhibitors

Merck KGaA and Pfizer discontinue JAVELIN Ovarian PARP 100 study of avelumab

Altimmune reports phase II extension study findings for NasoVAX intranasal influenza vaccine

Tesaro announces data from GARNET study of dostarlimab in endometrial cancer

Studies with cordycepin point to polyadenylation as a target for treating osteoarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...